The approval or clinical evaluation of several new agents - cabazitaxel, abiraterone acetate, enzalutamide, sipuleucel-T, and radium-223 - has changed the management of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to or after docetaxel-based chemotherapy significantly.
All of these agents have resulted in a significant survival benefit as compared to their control group. However, treatment responses might differ depending on the associated comorbidities and the extent and the biological aggressiveness of the disease. Furthermore, treatment associated side effects differ between the various drugs. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. It is the aim of the current article to: (1) summarize the data of established treatment options in mCRPC; (2) highlight new developments of medical treatment; (3) provide clinically useful algorithms for the daily routine and to (4) point out future developments of medical treatment.
Written by:
Heidenreich A, Porres D, Piper C, Thissen AK, Pfister D. Are you the author?
Department of Urology, RWTH University, Aachen, Germany.
Reference: Minerva Urol Nefrol. 2013 Sep;65(3):171-87.
PubMed Abstract
PMID: 23872628
UroToday.com mCRPC Treatment Section
